The PINK1 and PRKN enrichment was observed with the conversion of LC3-I to LC3-II in the mitochondrial fraction of pyrimethamine-treated ovarian cancer cells in a dose-dependent manner (Fig. 2G). Here, PRKN is linked to ovarian cancer.